company background image
REKA logo

Rekah Pharmaceutical Industry TASE:REKA Stok Raporu

Son Fiyat

₪13.76

Piyasa Değeri

₪157.1m

7D

1.1%

1Y

-5.0%

Güncellenmiş

03 Nov, 2024

Veri

Şirket Finansalları

Rekah Pharmaceutical Industry Ltd.

TASE:REKA Stok Raporu

Piyasa değeri: ₪157.1m

REKA Stoklara Genel Bakış

Rekah Pharmaceutical Industry Ltd. İsrail'de reçeteli ve reçetesiz ilaçların, dermo-kozmetiklerin, vitaminlerin ve besin takviyelerinin üretimi, pazarlanması, satışı ve dağıtımı ile ilgilenmektedir.

Rekah Pharmaceutical Industry Ltd. Rakipler

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Rekah Pharmaceutical Industry
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı₪13.76
52 Haftanın En Yüksek Seviyesi₪16.79
52 Haftanın En Düşük Seviyesi₪11.67
Beta0.042
11 Aylık Değişim-4.11%
3 Aylık Değişim-1.22%
1 Yıllık Değişim-5.04%
33 Yıllık Değişim-42.64%
5 Yıllık Değişim-39.73%
Halka arzdan bu yana değişim-96.07%

Son Haberler & Güncellemeler

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Jul 11
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Jul 05
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Dec 14
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Recent updates

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Jul 11
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Jul 05
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Dec 14
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Sep 12
Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Jul 19
Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

Apr 13
Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

May 12
We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Apr 09
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Mar 12
Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 19
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Jan 29
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

Jan 08
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Dec 18
How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

Nov 30
Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

Hissedar Getirileri

REKAIL PharmaceuticalsIL Pazar
7D1.1%4.3%3.3%
1Y-5.0%6.5%22.8%

Getiri vs. Endüstri: REKA underperformed the IL Pharmaceuticals industry which returned 5.8% over the past year.

Getiri vs Piyasa: REKA underperformed the IL Market which returned 25.4% over the past year.

Fiyat Oynaklığı

Is REKA's price volatile compared to industry and market?
REKA volatility
REKA Average Weekly Movement4.8%
Pharmaceuticals Industry Average Movement6.5%
Market Average Movement4.1%
10% most volatile stocks in IL Market7.4%
10% least volatile stocks in IL Market2.9%

İstikrarlı Hisse Senedi Fiyatı: REKA has not had significant price volatility in the past 3 months compared to the IL market.

Zaman İçindeki Volatilite: REKA's weekly volatility (5%) has been stable over the past year.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
1941427Mordechai Elgrabliwww.rekah.co.il

Rekah Pharmaceutical Industry Ltd. İsrail'de reçeteli ve reçetesiz ilaçların, dermo-kozmetiklerin, vitaminlerin ve besin takviyelerinin üretimi, pazarlanması, satışı ve dağıtımı ile ilgilenmektedir. Şirket steroid tabletleri; penisilin ve sefalosporin dahil antibiyotikler; alerji, enfeksiyon ve göz kuruluğunu tedavi etmek için damla ve merhemler; bebek ürünleri ve dermatolojik preparatlar sunmaktadır. Ürün portföyü, çeşitli tıbbi alanlarda kullanılan yaklaşık 280 ilaçtan oluşmaktadır.

Rekah Pharmaceutical Industry Ltd. Temel Bilgiler Özeti

Rekah Pharmaceutical Industry'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
REKA temel i̇stati̇sti̇kler
Piyasa değeri₪157.07m
Kazançlar(TTM)₪6.81m
Gelir(TTM)₪324.36m

23.1x

F/K Oranı

0.5x

P/S Oranı

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
REKA gelir tablosu (TTM)
Gelir₪324.36m
Gelir Maliyeti₪248.92m
Brüt Kâr₪75.45m
Diğer Giderler₪68.64m
Kazançlar₪6.81m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)0.60
Brüt Marj23.26%
Net Kâr Marjı2.10%
Borç/Özkaynak Oranı55.6%

REKA uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün